Barbra J Sasu
Overview
Explore the profile of Barbra J Sasu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin R, Sutton J, Bentley T, Vargas-Inchaustegui D, Nguyen D, Cheng H, et al.
Sci Adv
. 2023 Aug;
9(31):eadg8694.
PMID: 37540748
The magnitude of CAR T cell expansion has been associated with clinical efficacy. Although cytokines can augment CAR T cell proliferation, systemically administered cytokines can result in toxicities. To gain...
2.
Zhang Y, Tacheva-Grigorova S, Sutton J, Melton Z, Mak Y, Lay C, et al.
Clin Cancer Res
. 2023 Jan;
29(5):971-985.
PMID: 36692420
Purpose: Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options. Delta-like ligand 3 (DLL3) is highly expressed on SCLC and several other types of neuroendocrine cancers,...
3.
Sasu B, Opiteck G, Gopalakrishnan S, Kaimal V, Furmanak T, Huang D, et al.
Mol Ther
. 2022 Dec;
31(3):676-685.
PMID: 36518079
A chromosome 14 inversion was found in a patient who developed bone marrow aplasia following treatment with allogeneic chimeric antigen receptor (CAR) Tcells containing gene edits made with transcription activator-like...
4.
Lin R, Nager A, Park S, Sutton J, Lay C, Melton Z, et al.
Cancer Immunol Res
. 2022 Jul;
10(9):1069-1083.
PMID: 35881865
Although cytokine support can enhance CAR T-cell function, coadministering cytokines or engineering CAR T cells to secrete cytokines can result in toxicities. To mitigate these safety risks, we engineered iTurboCAR...
5.
Panowski S, Srinivasan S, Tan N, Tacheva-Grigorova S, Smith B, Mak Y, et al.
Cancer Res
. 2022 Mar;
82(14):2610-2624.
PMID: 35294525
Significance: These findings demonstrate the efficacy and safety of fratricide-resistant, allogeneic anti-CD70 CAR T cells targeting renal cell carcinoma and the impact of CAR epitope on functional activity. See related...
6.
Sommer C, Cheng H, Nguyen D, Dettling D, Yeung Y, Sutton J, et al.
Mol Ther
. 2020 Jun;
28(10):2237-2251.
PMID: 32592688
Patients with relapsed or refractory acute myeloid leukemia (AML) have a dismal prognosis and limited treatment options. Chimeric antigen receptor (CAR) T cells have achieved unprecedented clinical responses in patients...
7.
Panowski S, Kuo T, Zhang Y, Chen A, Geng T, Aschenbrenner L, et al.
Mol Cancer Ther
. 2019 Aug;
18(11):2008-2020.
PMID: 31434693
The restricted expression pattern of B-cell maturation antigen (BCMA) makes it an ideal tumor-associated antigen (TAA) for the treatment of myeloma. BCMA has been targeted by both CD3 bispecific antibody...
8.
Sommer C, Boldajipour B, Kuo T, Bentley T, Sutton J, Chen A, et al.
Mol Ther
. 2019 Apr;
27(6):1126-1138.
PMID: 31005597
Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a promising therapy for hematological...
9.
Steensma D, Sasu B, Sloan J, Tomita D, Loprinzi C
Blood
. 2015 Jun;
125(23):3669-71.
PMID: 26045598
No abstract available.
10.
Gardenghi S, Renaud T, Meloni A, Casu C, Crielaard B, Bystrom L, et al.
Blood
. 2013 Dec;
123(8):1137-45.
PMID: 24357729
Anemia of inflammation (AI) is commonly observed in chronic inflammatory states and may hinder patient recovery and survival. Induction of hepcidin, mediated by interleukin 6, leads to iron-restricted erythropoiesis and...